e-learning
resources
Stockholm 2002
Tuesday 17.09.2002
Tuberculosis management -2
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation of antituberculous drugs administration
S. E. Borissov, E. M. Belilovsky, S. M. Kuzkina, T. I. Morozova (Moscow, Saratov, Russia)
Source:
Annual Congress 2002 - Tuberculosis management -2
Session:
Tuberculosis management -2
Session type:
Thematic Poster Session
Number:
3390
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. E. Borissov, E. M. Belilovsky, S. M. Kuzkina, T. I. Morozova (Moscow, Saratov, Russia). Evaluation of antituberculous drugs administration. Eur Respir J 2002; 20: Suppl. 38, 3390
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Hepatotoxicity due to antituberculosis drug treatment
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II
Year: 2008
Rapid oral desensitization to anti-tuberculosis drugs
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Anti-tuberculosis drugs
Source: International Congress 2017 – State of the art session: "Respiratory infections"
Year: 2017
Initial antituberculosis drugs resistance
Source: Eur Respir J 2006; 28: Suppl. 50, 12s
Year: 2006
Manifestations of hypersensitivity to anti-tuberculosis drugs
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018
Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation?
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018
Cardiotoxicity of a complex of anti-tuberculosis drugs with the inclusion of fluoroquinolones and bedaquiline in an experiment on rats
Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection
Year: 2021
The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes
Source: Eur Respir J 2004; 24: Suppl. 48, 654s
Year: 2004
Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020
Year: 2020
Side-effect in the treatment of pulmonary tuberculosis by first-line drugs
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009
Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001
Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis
Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues
Year: 2019
Paradoxical response to adequate antituberculosis treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 724s
Year: 2004
Desensitization therapy for allergic reactions of antituberculous drugs
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Incidence and timing of hepatotoxicity due to anti-tuberculous treatment
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Comparison of anti-tuberculosis regimens using fixed dose combination versus single drugs
Source: Annual Congress 2010 - Prognosis of tuberculosis
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept